Alendronate induces skeletal alterations in the chicken embryonic development model

Area of Science:

• Pharmacology
• Developmental Biology
• Orthopedics

Background:

• Alendronate, a nitrogen-containing bisphosphonate, is widely used for osteoporosis but its effects on osteoblasts and embryonic development are less understood.
• Alendronate can cross the placental barrier, raising concerns for pregnant women of reproductive age undergoing alendronate therapy.
• Understanding alendronate's impact on embryonic bone development is crucial given its potential teratogenic effects.

Purpose of the Study:

• To investigate the dose-dependent effects of alendronate on embryonic skeletal development.
• To assess alendronate's influence on osteogenic and osteoclastogenic gene expression and inflammatory activation in developing bone.
• To evaluate the safety of alendronate during embryonic development using a translational animal model.

Main Methods:

• Utilized a chicken embryo model, exposing embryos to varying alendronate concentrations (1.5E^-10M to 1.5E^-7M) from day 7 of osteogenesis for 4 days.
• Conducted histomorphometric analysis with histochemical staining and microtomographic analysis to assess skeletal development and mineralization.
• Performed gene expression analysis for osteoclastogenic, osteogenic, and inflammatory markers.

Main Results:

• Alendronate exposure demonstrated a dose-dependent inhibition of skeletal growth and mineralization, with a significant reduction in bone volume and surface at 1.5E^-7M.
• Decreased expression of osteoclastogenic/osteoclastic genes and osteoblastogenic/osteogenic genes (30-50% reduction at 1.5E^-7M) indicated impaired bone formation.
• Evidence of increased inflammatory activation was observed, potentially contributing to the observed negative effects on bone development.

Conclusions:

• Alendronate exerts a dose-dependent negative influence on embryonic bone development.
• The findings highlight potential risks associated with alendronate exposure during critical periods of embryonic skeletal formation.
• Further research is warranted to fully elucidate the mechanisms and clinical implications of alendronate's effects on embryonic development.